NYXH

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequentially to €2.5 million.

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium – August 5, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2026. Financial and Operating Highlights Financials U.S. net revenue for the second quarter of 2026 was €5.2 million, 22% sequential growth over U.S. net revenue for the first quarter of 2026 Global net revenue for the second quarter of 2026 was €7.7 million, 21% sequential growth over global net revenue for the first quarter of 2026 Global net revenue for the first half of 2026 was €14.0 million, as compared to €2.4 million for the first half of 2025 Secured $110 million in aggregate financing during the second quarter of 2026.

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2026 on Wednesday, August 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Nyxoah SA (NYXH) Analyst/Investor Day Transcript

Nyxoah Announces Preliminary Results for the Second Quarter of 2026 Continued U.S. launch momentum drives second quarter global preliminary net revenue of €7.7 million CMS proposes 2027 OPPS and ASC payment increase of 12% and 15% respectively Mont-Saint-Guibert, Belgium – July 7, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited second quarter 2026 financial and operating results. Second Quarter 2026 – Preliminary Sales and Market Metrics Financials Global net revenue is expected to be approximately €7.7 million in the second quarter of 2026, which reflects 21% sequential growth over the first quarter of 2026 U.S. net revenue is expected to be approximately €5.2 million in the second quarter of 2026, which reflects 22% sequential growth over the first quarter of 2026 Leading U.S. commercial indicators 55 new surgeons trained in Q2, bringing the total to 262 surgeons trained 89 new accounts activated in Q2, bringing the total to 180 active high-volume accounts 427 patients submitted under prior authorization entering Q3 Reimbursement US CMS is proposing to increase hospital reimbursement for the Genio procedure (C8011) from $31,526 to $35,414, representing an increase of $3,888 (12%) CMS is proposing to increase ASC reimbursement from $27,563 to $31,722, an increase of $4,159 (15%) Liquidity $110 million in aggregate financing secured in Q2 As of June 30, 2026, cash, cash equivalents and financial assets are expected to be approximately €97.8 million "We closed Q2 with clear U.S. momentum: the scaling of our U.S. sales force allowed us to double the number of active accounts to 180 high-volume HGNS accounts and deliver a second consecutive quarter of over 20% sequential U.S. revenue growth.

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issuance of 146,531 new shares on June 30, 2026 following the exercise of so-called “restricted share units”. Share capital: EUR 7,075,152.31 Total number of securities carrying voting rights: 100,072,815 (all ordinary shares) Total number of voting rights (= denominator): 100,072,815 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 3,731,884 (all granted subscription rights; this number excludes 36,125 subscription rights that were issued but not yet granted) Total number of convertible bonds: 225 convertible bonds with a nominal value of EUR 83,000 per bond Total number of voting rights that can be obtained in case of conversion of all 225 convertible bonds at the current (revised) conversion price of EUR 1.48 per share: 12,618,243 (this number does not take into account the conversion of interest) * * * Contact: Nyxoah John Landry, CFOIR@nyxoah.com Attachment 2026 06 30 - Press release - Number of shares (ENG)

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 29, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received transparency notifications as detailed below. Orin Hirchman On June 24, 2026, Nyxoah received a transparency notification from Orin Hirchman following an acquisition of voting securities by entities controlled by Orin Hirchman.

Nyxoah to Host Investor Day in New York on July 8, 2026 Leadership team and Board will discuss the U.S. commercial execution, growth strategy and key priorities Mont-Saint-Guibert, Belgium – June 23, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it will host an Investor and Analyst Day on Wednesday, July 8, 2026, in New York. The event will be held at the offices of Bank of America and will run from 10:00 AM to 12:30 PM ET (16:00 to 18:30 CET).

REGULATED INFORMATION June 19, 2026, 10:30pm CET / 4:30pm ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders' meeting of the Company to be held on July 9, 2026 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Thursday, July 9, 2026 at 2:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time.